Table 1.
Pre-implant characteristics of the sample
| Characteristic (mean±SD or n (%)) | Full Sample (n=86) | Bridge (n=64) | Destination (n=22) | p-value |
|---|---|---|---|---|
| Patient age (in years) | 53.0 ± 14.4 | 49.2 ± 14.1 | 64.1 ± 8.4 | <0.001 |
| Female | 18 (20.9%) | 14 (21.9%) | 4 (18.2%) | 0.713 |
| Caucasian | 72 (83.7%) | 51 (79.7%) | 21 (95.5%) | 0.628 |
| Body Mass Index (kg/m2) | 29.0 ± 5.5 | 28.8 ± 5.3 | 29.6 ± 6.1 | 0.590 |
| Former vs never smokers | 54 (62.8%) | 36 (56.3%) | 18 (81.8%) | 0.032 |
| Diabetes with end-organ damage | 9 (10.5%) | 3 (4.7%) | 6 (27.3%) | 0.026 |
| Stage 3 chronic kidney disease | 34 (39.5%) | 21 (32.8%) | 13 (59.1%) | 0.030 |
| Sleep disordered breathing | 41 (47.7%) | 26 (40.6%) | 15 (68.2%) | 0.026 |
| Depressive/anxiety disorder | 13 (15.1%) | 8 (12.5%) | 5 (22.7%) | 0.248 |
| Antidepressant/anxiolytic therapy | 24 (27.9%) | 16 (25.0%) | 6 (27.3%) | 0.833 |
| Ischemic Etiology | 29 (33.7%) | 17 (26.6%) | 12 (54.6%) | 0.022 |
| New York Heart Association Class III/IV | 83 (96.5%) | 61 (95.3%) | 22 (100%) | 0.142 |
| Left ventricular ejection fraction (%) | 20.4 ± 3.0 | 20.4 ± 3.3 | 20.5 ± 2.0 | 0.838 |
| Left ventricular internal diastolic diameter (cm) | 7.4 ± 1.2 | 7.4 ± 1.2 | 7.3 ± 1.1 | 0.847 |
| PCWP (mm Hg) | 23.4 ± 8.6 | 23.9 ± 8.7 | 22.0 ± 8.3 | 0.363 |
| RAP (mm Hg) | 9.3 ± 4.8 | 9.4 ± 9 | 8.9 ± 4.7 | 0.674 |
| Cardiac Index (by Fick equation) (L/min/m2) | 1.9 ± 0.5 | 1.9 ± 0.5 | 1.9 ± 0.5 | 0.859 |
| V02 max (L/min) | 12.4 ± 4.8 | 13.2 ± 5.1 | 10.1 ± 2.5 | 0.062 |
| Serum Sodium (mEq/L) | 134.5 ± 4.3 | 134.8 ± 3.9 | 133.5 ± 5.4 | 0.285 |
| Serum Hemoglobin (%) | 11.9 ± 1.9 | 11.7 ± 1.8 | 12.6 ± 2.2 | 0.098 |
| Continuous Inotropic Support | 52 (60.5%) | 41 (64.1%) | 11 (50.0%) | 0.403 |
| Intra-aortic Balloon Pump | 33 (38.4%) | 27 (42.2%) | 6 (27.3%) | 0.215 |
Abbreviations: PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure.